Fig. 1From: A novel signature of two long non-coding RNAs in BRCA mutant ovarian cancer to predict prognosis and efficiency of chemotherapyStudy protocol. The order of analyses to develop the risk score model and validate the efficiency of the signature to predict prognostic outcomesBack to article page